- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01293383
A Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects
March 25, 2015 updated by: LEO Pharma
A Phase 1 Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects. A Single Centre, Prospective, Randomised, Double-blinded, Vehicle-controlled Clinical Study
The purpose of this trial is to to investigate the safety of LEO 90105 compared with its vehicle after multiple administration (twice daily, 5 days) in healthy Japanese male subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Fukuoka, Japan, 812-0025
- Hakata Clinic LTA Clinical Pharmacology Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy Japanese male subjects
- Aged 20 to 40 years inclusive
- Subjects without signs of skin irritation (erythema, dryness, roughness or scaling) on the test site
- Subjects willing to follow the study procedures and complete the study
- Subjects having understood and signed a written informed consent
- Subjects without abnormal in physiological test and clinical test in screening, and also judged as possible to participant the study by investigators
Exclusion Criteria:
- Subjects with Body mass Index (BMI ) (body weight(kg)/height (m)²) outside the range 18-25 kg/m2(18≤BMI<25)
- Subjects with history of alcohol, chemical or drug abuse
- Subjects with history of allergic reaction to any content of the study medication
- Subjects with systemic or cutaneous disease that could in any way confound interpretation of the study results (e.g. atopic dermatitis, eczema, psoriasis)
- Subjects with known sensitivity to any component of any of the formulations being tested
- Subjects with known hepatic, renal or cardiac disorders
- Subjects using systemic, locally injected or inhaled corticosteroids within 4 weeks of study start (Day 1)
- Subjects using systemic vitamin D analogues,vitamin D or calcium supplements within 4 weeks of study start (Day 1)
- Subjects using any drug (systemic or topical) within 2 weeks of study start (Day 1)
- Subjects using non-marketed/other investigational products one month prior to or 5 half lives (for those the half life is longer than one month) and during the trial is not permitted
- Subjects with any abnormality found at medical interview before administration of the test drug, which will affect the clinical study as judged by the investigator
- Subjects with history of or active photo-induced or photo-aggravated disease (abnormal response to the sun light)
- Subjects with exposure to excessive or chronic ultraviolet (UV) radiation i.e., sunbathing, tanning salon use, phototherapy) within four weeks prior to study start (Day 1) or planned during the study period
- Subjects with scars, moles, sunburn, or other blemishes in the test area which would interfere with grading
- Subjects whose partner wishes to become pregnant but is unwilling to use birth control during the study
- Subjects with any condition which, in the opinion of the investigator, would place the subject at an unacceptable risk if he participated in the study
- Subjects with any disease which are contradictions for treatment of the investigation products or for which treatment with the investigation products needs to be carefully considered (Subjects with any of the following conditions present on the area(s) to be treated with study medication: viral (e.g., herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers or wounds)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Vehicle
|
Ointment
|
Other: LEO 90105
|
Ointment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Skin irritation
Time Frame: 6 days
|
6 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Masanari Shiramoto, MD., PhD, Hakata Clinic LTA Clinical Pharmacology Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
March 1, 2011
Study Registration Dates
First Submitted
February 9, 2011
First Submitted That Met QC Criteria
February 9, 2011
First Posted (Estimate)
February 10, 2011
Study Record Updates
Last Update Posted (Estimate)
March 26, 2015
Last Update Submitted That Met QC Criteria
March 25, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Other Study ID Numbers
- MCB 0902
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on LEO 90105
-
LEO PharmaQuintiles, Inc.Completed
-
LEO PharmaCompleted
-
LEO PharmaCompleted
-
LEO PharmaCompleted
-
LEO PharmaCompleted
-
LEO PharmaCompletedActinic KeratosisUnited States
-
LEO PharmaCompletedAtopic DermatitisUnited Kingdom
-
LEO PharmaCompletedActinic KeratosisUnited States
-
LEO PharmaCompleted
-
LEO PharmaTerminatedAtopic DermatitisGermany